Citizens lowered the firm’s price target on Nasus Pharma (NSRX) to $18 from $19 and keeps an Outperform rating on the shares. Following the quarterly results, the firm believes NS002 has best-in-class potential, supported by positive results from its Phase 2 studies, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRX:
- Nasus Pharma Moves Intranasal Epinephrine Toward Pivotal Trial After Positive Phase 2 Results
- Nasus Pharma advances NS002 to pivotal study following Phase 2 results
- Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)
- Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
- Nasus Pharma’s NS002 Outperforms EpiPen in Phase 2 Anaphylaxis Study, Pivotal Trial Planned for Late 2026